Soligenix announces positive clinical results from compatibility study of hybryte™ in the treatment of cutaneous t-cell lymphoma

Results confirm and extend response results from phase 3 flash study princeton, n.j. , may 4, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive clinical results from a compatibility study evaluating hybryte™ (synthetic hypericin sodium) in the treatment of cutaneous t-cell lymphoma (ctcl) using the commercially ready daavlin series 7 visible light device, which recently received 510(k) clearance from u.s. food and drug administration (fda).
SNGX Ratings Summary
SNGX Quant Ranking